Chinese drug maker Chuanelle Pharmaceuticals is under investigation by the Food and Drug Administration (FDA) for the first time in the history of the agency, The Wall Street Journal reported. In March, the FDA issued a public warning after discovering that Chuanelles Chloroquine was a precursor to the highly-toxic E.coli coronavirus (COVID) vaccine.
The company is also facing scrutiny from other countries after the FDA announced that it had shut down a manufacturing plant in China, after discovering its coronavirus vaccine was contaminated with the COVID-19 virus.
According to The Wall Street Times, Chuanelle’s investigation found that Churner Pharmaceuticals manufactured the Chuanella vaccine in China for the Bacon Industries of China company, which had received a $1.9 million contract to manufacture the vaccine.
According to The Wall St Journal, Bachem, which was acquired by Chuaneles Churners, was involved in a “massive” COVID outbreak that killed more than 2,500 people and caused nearly $1 billion in damages. Churner’s chief executive, Shuqing Wang, has received an undisclosed amount of US government grants for his government work, according to New York Magazine.
As The FDA investigates Chuanela’s coronal pandemic, Chinese companies are increasingly becoming the focus of regulatory scrutiny, especially in the wake of a major pandemic in India that sparked an unprecedented rise in the number of new cases of COVID.
Last week, a new outbreak in New Jersey was linked to Chuangeles Chloroquines.
It was first reported by The Associated Press.